N-acetylheparin pretreatment reduces infarct size in the rabbit

Pharmacology

Volumn 58, Issue 3, 1999, Pages 120-131

  Park, James L ^a   Kilgore, Kenneth S ^a   Naylor, Keith B ^a   Booth, Erin A ^a   Murphy, Kerri L ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Complement activation; Cytokines; Ischemia; Leukocytes; Rabbit

Indexed keywords

COMPLEMENT; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEPARIN DERIVATIVE; INTERLEUKIN 8; MYELOPEROXIDASE; N ACETYLHEPARIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; CALCIUM; COMPLEMENT MEMBRANE ATTACK COMPLEX; HEMODYNAMIC PROCESSES; HEPARIN; INTERLEUKIN-8; LEUKOCYTE COUNT; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHIL ACTIVATION; PEROXIDASE; RABBITS;

EID: 0032923498     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028274     Document Type: Article

References (30)

1. Black SC, Gralinski MR, Friedrichs GS, Kilgore KS, Driscoll EM, Lucchesi BR: Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-636.
2. Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR: Effects of heparin and N-acetylheparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-710.
3. Rent R, Ertel N, Eisenstein R, Gewurz H: Complement activation by interaction of polyanions and polycations. I. Heparin-protamine induced consumption of complement. J Immunol 1975;114:120-124.
4. Weiler JM, Yurt RW, Fearon DT, Austen KF: Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 1978;147:409-421.
5. Sharath MD, Merchant ZM, Kim YS, Rice KG, Linhardt RJ, Weiler JM: Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology 1985;9:73-80.
6. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA: Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975;56:740-750.
7. Vakeva A, Morgan BP, Tikkanen I, Helin K, Laurila P, Meri S: Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol 1994;144:1357-1368.
8. Weiler JM, Edens RE, Linhardt RJ, Kapelanski DP: Heparin and modified heparin inhibit complement activation in vivo. J Immunol 1992; 148:3210-3215.
9. Gralinski MR, Driscoll EM, Friedrichs GS, DeNardis MR, Lucchesi BR: Reduction of myocardial necrosis after glycosaminoglycan administration: Effects of a single intravenous administration of heparin or N-acetylheparin 2 hours before regional ischemia and reperfusion. J Cardiovasc Pharmacol Ther 1996;1: 219-228.
10. Rendlund DG, Macfarlane JL, Christensen RD, Lynch RE, Rothstein G: A quantitative and sensitive method for measurement of myeloperoxidase (abstract). Clin Res 1980;28:75A.
11. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982;78:206-209.
12. Mulligan MS, Hevel JM, Marletta MA, Ward PA: Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci USA 1991;88:6338-6342.
13. Varani J, Ginsburg I, Schuger L, Gibbs DF, Bromberg J, Johnson KJ, Ryan US, Ward PA: Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol 1989;135: 435-438.
14. Thompson AK, Mostafapour SP, Denlinger LC, Bleasdale JE, Fisher SK: The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. J Biol Chem 1991;266:23856-23862.
15. Mathey D, Schofer J, Schafer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S: Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994;15:418-423.
16. Broaddus VC, Boylan AM, Hoeffel JM, Kim KJ, Sadick M, Chuntharapai A, Hebert CA: Neutralization of IL-8 inhibits neutrophil influx in a rabbit model of endotoxin-induced pleurisy. J Immunol 1994;52:2960-2965.
17. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
18. Hill JH, Ward PA: The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971;133:885-900.
19. Pinckard RN, Olson MS, Giclas PC, Terry R, Boyer JT, O'Rourke RA: Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J Clin Invest 1975;56:740-750.
20. Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, Entman ML: Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle: A possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res 1985;57: 119-130.
21. Schafer H, Mathey D, Hugo F. Bhakdi S: Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol 1986;137:1945-1949.
22. Mathey D, Schofer J, Schäfer HJ, Hamdoch T, Joachim HC, Ritgen A, Hugo F, Bhakdi S: Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion. Eur Heart J 1994;15:418-423.
23. Herskowitz A, Choi S, Ansari AA, Wesselingh S: Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995; 146:419-428.
24. Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS: Enhancement by the complement membrane attack complex of tumor necrosis factor-α-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995;155:1434-1441.
25. Ecker EE, Gross P: Anticomplementary power of heparin. J Infect Dis 1929;44:250-253.
26. Meri S, Pangburn MR: Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994;198:52-59.
27. Silvestro L, Viano I, Macario M, Colangelo D, Montrucchio G, Panico S, Fantozzi R: Effects of heparin and its desulphated derivatives on leukocyte-endothelial adhesion. Semin Thromb Hemost 1994;20:254-258.
28. Tanaka Y, Adams DH, Shaw S: Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111-115.
29. Hiebert LM, Jaques LB: Heparin uptake on endothelium. Artery 1976;2:26-37.
30. Edens R, Linhardt RJ, Weiler JM: Heparin is not just an anticoagulant anymore: Six and one-half decades of studies on the ability of heparin to regulate complement activity; in Cruse JM, Lewis RE Jr (eds): Complement Today. Basel, Karger, 1993, pp 96-120.